Binbin Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Binbin Cheng has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Jianjun Chen
Guangdong Provincial Key Laboratory of New Drug Screening, NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China
12 shared publications - Xiaopeng Peng
College of Pharmacy, Gannan Medical University, Ganzhou, 314000, China
6 shared publications - Yao Xiao
Wuchang Hospital Affiliated to Wuhan University of Science and Technology, Wuhan Wuchang Hospital, Wuchang 430063, China
4 shared publications - Yingxing Zhou
Hubei Key Laboratory for Kidney Disease Pathogenesis and Intervention, Hubei Polytechnic University, Huangshi, Hubei, 435003, China; Huangshi Key Laboratory of Molecular Diagnosis and Individualized Treatment, Huangshi Love&health Hospital Affiliated of Hubei Polytechnic University, China
4 shared publications - Chuxiao Shao
Central Laboratory, Wenzhou Medical University Lishui Hospital, Lishui People's Hospital, Lishui, Zhejiang, 323000, China
3 shared publications - Wei Pan
Geriatric Department, Affiliated Foshan Women and Children Hospital, Guangdong Medical University, China
3 shared publications
Latest Publications
- 1 June 2026
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 12 (6) , 2136-2148
Efavirenz Mitigates Dyslipidemia and Attenuates Ulcerative Colitis through Gut Microbiota Modulation
Antiretroviral therapy (ART) is central to controlling human immunodeficiency virus (HIV) infection, yet it is frequently associated with dyslipidemia, a condition linked to the exacerbation of ulcerative colitis (UC) in people living with HIV (PLWH). The underlying mechanisms of ART-induced dyslipidemia and its contribution to UC progression remain incompletely understood. Here, we demonstrate that efavirenz (EFV), a widely used non-nucleoside reverse transcriptase inhibitor, mitigates ART-induced dyslipidemia and ameliorates UC symptoms. Our in vitro investigations reveal that palmitic acid (PA)-induced inflammation in human normal colorectal mucosal cells (FHCs) is mediated by the activation of the Akt phosphorylation pathway, triggered by the accumulation of 7-dehydrocholesterol (7-DHC), a substrate of 7-dehydrocholesterol reductase (DHCR7). While EFV did not directly modulate this inflammatory cascade in FHCs, in vivo studies using a high-fat diet (HFD)-induced dyslipidemia rat model demonstrated that EFV significantly attenuated elevated lipid levels and improved DHCR7 expression in dextran sulfate sodium (DSS)-induced UC tissues. Notably, fecal microbiota transplantation (FMT) from EFV-treated rats to HFD-fed recipients reduced dyslipidemia and restored DHCR7 expression, thereby suppressing 7-DHC-driven Akt phosphorylation and inflammatory responses in UC tissues. Our findings suggest a mechanism by which EFV mitigates dyslipidemia and UC progression, mediated through the regulation of lipid metabolism and gut microbiota. These findings provide compelling evidence for the potential of EFV to regulate dyslipidemia and associated comorbidities in HIV-infected individuals.
- 1 June 2026
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 12 (6) , 2136-2148
Efavirenz Mitigates Dyslipidemia and Attenuates Ulcerative Colitis through Gut Microbiota Modulation
Antiretroviral therapy (ART) is central to controlling human immunodeficiency virus (HIV) infection, yet it is frequently associated with dyslipidemia, a condition linked to the exacerbation of ulcerative colitis (UC) in people living with HIV (PLWH). The underlying mechanisms of ART-induced dyslipidemia and its contribution to UC progression remain incompletely understood. Here, we demonstrate that efavirenz (EFV), a widely used non-nucleoside reverse transcriptase inhibitor, mitigates ART-induced dyslipidemia and ameliorates UC symptoms. Our in vitro investigations reveal that palmitic acid (PA)-induced inflammation in human normal colorectal mucosal cells (FHCs) is mediated by the activation of the Akt phosphorylation pathway, triggered by the accumulation of 7-dehydrocholesterol (7-DHC), a substrate of 7-dehydrocholesterol reductase (DHCR7). While EFV did not directly modulate this inflammatory cascade in FHCs, in vivo studies using a high-fat diet (HFD)-induced dyslipidemia rat model demonstrated that EFV significantly attenuated elevated lipid levels and improved DHCR7 expression in dextran sulfate sodium (DSS)-induced UC tissues. Notably, fecal microbiota transplantation (FMT) from EFV-treated rats to HFD-fed recipients reduced dyslipidemia and restored DHCR7 expression, thereby suppressing 7-DHC-driven Akt phosphorylation and inflammatory responses in UC tissues. Our findings suggest a mechanism by which EFV mitigates dyslipidemia and UC progression, mediated through the regulation of lipid metabolism and gut microbiota. These findings provide compelling evidence for the potential of EFV to regulate dyslipidemia and associated comorbidities in HIV-infected individuals.
- 16 February 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (4) , 4913-4931
Discovery of Novel Heterotetracyclic DNA-Dependent Protein Kinase (DNA-PK) Inhibitors with Improved Oral Bioavailability and Potent Cancer Immunotherapy-Potentiating Activity
A novel series of heterotetracyclic DNA-PK inhibitors was rationally designed, synthesized, and biologically evaluated. Most compounds showed potent DNA-PK inhibition (IC50: 10.2-88.9 nM), with lead D11 (IC50 = 10.2 nM) inducing γH2A.X upregulation and robust antiproliferative activity across six cancer cell lines. Remarkably, D11 exhibited excellent pharmacokinetics in SD rats (oral bioavailability: 42.6%; half-life: 50 h) and outperformed the clinical candidate AZD-7648 in LoVo xenografts (TGI = 72.9% vs 54.6% at 50 mg/kg, p.o.). It also synergized with anti-PD-L1 mAb to enhance CD8+ T-cell infiltration. Overall, D11 is a promising heterotetracyclic DNA-PK inhibitor with superior in vivo efficacy, favorable pharmacokinetics, and immunomodulatory potential, supporting further development.
- 16 February 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (4) , 4913-4931
Discovery of Novel Heterotetracyclic DNA-Dependent Protein Kinase (DNA-PK) Inhibitors with Improved Oral Bioavailability and Potent Cancer Immunotherapy-Potentiating Activity
A novel series of heterotetracyclic DNA-PK inhibitors was rationally designed, synthesized, and biologically evaluated. Most compounds showed potent DNA-PK inhibition (IC50: 10.2-88.9 nM), with lead D11 (IC50 = 10.2 nM) inducing γH2A.X upregulation and robust antiproliferative activity across six cancer cell lines. Remarkably, D11 exhibited excellent pharmacokinetics in SD rats (oral bioavailability: 42.6%; half-life: 50 h) and outperformed the clinical candidate AZD-7648 in LoVo xenografts (TGI = 72.9% vs 54.6% at 50 mg/kg, p.o.). It also synergized with anti-PD-L1 mAb to enhance CD8+ T-cell infiltration. Overall, D11 is a promising heterotetracyclic DNA-PK inhibitor with superior in vivo efficacy, favorable pharmacokinetics, and immunomodulatory potential, supporting further development.
- Open Access
- 25 November 2025
- Published by Elsevier in Journal of Advanced Research
- Vol. 86, 959-980
Spop-binding bifunctional degraders: a novel approach for cancer immunotherapy
- 25 November 2025
- Published by Elsevier in Journal of Advanced Research
- Vol. 86, 959-980
Open AccessSpop-binding bifunctional degraders: a novel approach for cancer immunotherapy
- 15 July 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (14) , 15228-15229
Correction to “Small-Molecule Modulators Targeting Coactivator-Associated Arginine Methyltransferase 1 (CARM1) as Therapeutic Agents for Cancer Treatment: Current Medicinal Chemistry Insights and Emerging Opportunities”
- 15 July 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (14) , 15228-15229
Correction to “Small-Molecule Modulators Targeting Coactivator-Associated Arginine Methyltransferase 1 (CARM1) as Therapeutic Agents for Cancer Treatment: Current Medicinal Chemistry Insights and Emerging Opportunities”
- 15 July 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 297, 117966
Rational design of NAMPT-based dual inhibitors with improved drug-like and pharmacokinetic properties for cancer treatment
- 15 July 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 297, 117966
Rational design of NAMPT-based dual inhibitors with improved drug-like and pharmacokinetic properties for cancer treatment
- 26 June 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (13) , 13169-13185
Research Progress in Targeting GSPT1: Molecular Glues, Bifunctional Degraders, and Antibody-Enabled Molecular Glues for Cancer Therapy
G1 to S phase transition 1 (GSPT1, also known as eRF3a) is a crucial translation termination factor that plays a vital role in acute myeloid leukemia (AML) and MYC-driven lung cancer. Degrading GSPT1 can induce apoptosis in cancer cells and reduce their viability, thus making GSPT1 a potential therapeutic target. This perspective aims to introduce the current research status of the mechanism of molecular glues targeting GSPT1, summarize the recent progress in and challenges for existing molecular glues, bifunctional degraders, and antibody-enabled molecular glues targeting GSPT1, and outline the development strategies for targeting GSPT1 in the treatment of cancer.
- 26 June 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (13) , 13169-13185
Research Progress in Targeting GSPT1: Molecular Glues, Bifunctional Degraders, and Antibody-Enabled Molecular Glues for Cancer Therapy
G1 to S phase transition 1 (GSPT1, also known as eRF3a) is a crucial translation termination factor that plays a vital role in acute myeloid leukemia (AML) and MYC-driven lung cancer. Degrading GSPT1 can induce apoptosis in cancer cells and reduce their viability, thus making GSPT1 a potential therapeutic target. This perspective aims to introduce the current research status of the mechanism of molecular glues targeting GSPT1, summarize the recent progress in and challenges for existing molecular glues, bifunctional degraders, and antibody-enabled molecular glues targeting GSPT1, and outline the development strategies for targeting GSPT1 in the treatment of cancer.
- 20 February 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (5) , 5426-5454
Discovery of Novel and Highly Potent Dual PD-L1/Histone Deacetylase 6 Inhibitors with Favorable Pharmacokinetics for Cancer Immunotherapy
A series of novel PD-L1/HDAC6 dual inhibitors were designed and synthesized, and compound HP29 was identified as the most potent candidate, which demonstrated excellent and selective HDAC6 inhibitory activity (IC50 = 78 nM, SI > 1282), and high anti-PD-1/PD-L1 activity (IC50 = 26.8 nM). Further studies showed that HP29 could bind with high affinity to PD-L1 and HDAC6 protein. Furthermore, HP29 possessed favorable in vivo pharmacokinetic properties, such as decent oral bioavailability (F = 15.3%). Moreover, HP29 exhibited significant in vivo antitumor efficacy in a melanoma tumor model with a greater tumor growth inhibition (TGI) (65.5%) than that of NP19 (43.2%), ACY-1215 (45.6%), and the combination group (53.9%). Mechanistically, the percentages of tumor-infiltrating lymphocytes (TILs) in the HP29-treated tumor tissues were significantly higher than the combination group or PD-L1 inhibitor monotherapy group, suggesting potential synergistic antitumor immune effects. Collectively, HP29 represents a novel PD-L1/HDAC6 dual inhibitor deserving further investigation as a potential cancer immunomodulating agent.
- 20 February 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (5) , 5426-5454
Discovery of Novel and Highly Potent Dual PD-L1/Histone Deacetylase 6 Inhibitors with Favorable Pharmacokinetics for Cancer Immunotherapy
A series of novel PD-L1/HDAC6 dual inhibitors were designed and synthesized, and compound HP29 was identified as the most potent candidate, which demonstrated excellent and selective HDAC6 inhibitory activity (IC50 = 78 nM, SI > 1282), and high anti-PD-1/PD-L1 activity (IC50 = 26.8 nM). Further studies showed that HP29 could bind with high affinity to PD-L1 and HDAC6 protein. Furthermore, HP29 possessed favorable in vivo pharmacokinetic properties, such as decent oral bioavailability (F = 15.3%). Moreover, HP29 exhibited significant in vivo antitumor efficacy in a melanoma tumor model with a greater tumor growth inhibition (TGI) (65.5%) than that of NP19 (43.2%), ACY-1215 (45.6%), and the combination group (53.9%). Mechanistically, the percentages of tumor-infiltrating lymphocytes (TILs) in the HP29-treated tumor tissues were significantly higher than the combination group or PD-L1 inhibitor monotherapy group, suggesting potential synergistic antitumor immune effects. Collectively, HP29 represents a novel PD-L1/HDAC6 dual inhibitor deserving further investigation as a potential cancer immunomodulating agent.
- 31 January 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 287, 117347
Research progress in DNA damage response (DDR)-targeting modulators: From hits to clinical candidates
- 31 January 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 287, 117347
Research progress in DNA damage response (DDR)-targeting modulators: From hits to clinical candidates
- 19 January 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 286, 117289
Research progress in bifunctional small molecules for cancer immunotherapy
- 19 January 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 286, 117289
Research progress in bifunctional small molecules for cancer immunotherapy
- 27 December 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 284, 117212
Recent advances in developing targeted protein degraders
- 27 December 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 284, 117212
Recent advances in developing targeted protein degraders